



Sorting of growth hormone–erythropoietin fusion proteins in rat salivary glands

Yuval Samuni^{a,*}, Changyu Zheng^a, Niamh X. Cawley^b, Ana P. Cotrim^a, Y. Peng Loh^b, Bruce J. Baum^a

^a Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, USA

^b Section of Cellular Neurobiology, National Institute of Child Health and Human Development, USA

ARTICLE INFO

Article history:

Received 23 May 2008

Available online 9 June 2008

Keywords:

Adenovirus
Gene therapeutics
Protein secretion
Protein sorting
Salivary glands

ABSTRACT

Neuroendocrine and exocrine cells secrete proteins in either a constitutive manner or via the regulated secretory pathway (RSP), but the specific sorting mechanisms involved are not fully understood. After gene transfer to rat salivary glands, the transgenic model proteins human growth hormone (hGH) and erythropoietin (hEpo) are secreted primarily into saliva (RSP; exocrine) and serum (constitutive; endocrine), respectively. We hypothesized that fusion of hGH at either the C-terminus or the N-terminus of hEpo would re-direct hEpo from the bloodstream into saliva. We constructed and expressed two fusion proteins, hEpo-hGH and hGH-hEpo, using serotype 5-adenoviral vectors, and delivered them to rat submandibular glands *in vivo* via retroductal cannulation. Both the hEpo-hGH and hGH-hEpo fusion proteins, but not hEpo alone, were secreted primarily into saliva ($p < 0.0001$ and $p = 0.0083$, respectively). These *in vivo* studies demonstrate for the first time that hGH, in an N- as well as C-terminal position, influences the secretion of a constitutive pathway protein.

Published by Elsevier Inc.

Sorting mechanisms of secretory proteins are not fully understood. The prevailing paradigm describes two general pathways for sorting of secretory proteins in polarized cells [1,2]. In the first, proteins are secreted as fast as they are synthesized, in a constitutive, non-directional manner and independent from changes in second messenger levels. In the second pathway, the regulated secretory pathway (RSP), proteins destined for secretion are sorted and stored in high concentrations in secretory granules where they await an external secretory stimulus [3–5]. RSP proteins require an amino acid-based sorting signal and evidence supports both the “sorting-for-entry” and “sorting-by-retention” hypotheses for these proteins [6–10]. At present no universal sorting signals for secretory proteins have been identified in any cell type. Additionally, most studies of secretory protein sorting have been performed in transformed cell lines *in vitro*, with few studies performed *in vivo* or with acutely prepared primary cells [8,11–14]. However, it is clear that specific proteins can be sorted differently in various cell types, and transformed cell lines may exhibit dramatically different secretory protein sorting behaviors than primary cells or the native cells *in situ* [8,13].

Several distinct protein secretion pathways have been identified in salivary gland cells, within the general constitutive and RSP categories, including both major and minor regulated pathways, apical and basolateral constitutive pathways, and a constitutive-like

pathway [9,15]. These lead to specific sorting routes for transgenic secretory proteins in an endocrine and exocrine manner [16]. For example, human growth hormone (hGH), which in the anterior pituitary gland is secreted into the bloodstream via the RSP, when expressed from an adenoviral vector delivered to rodent and miniature pig salivary glands, follows the tissue specific RSP, i.e., the exocrine route into saliva [17–19]. Conversely, transgenic human erythropoietin (hEpo) is secreted from murine salivary glands almost entirely via an endocrine route into the bloodstream [20–22]. Ideally, control over protein entry into either of these general pathways could provide a means for selectively directing transgene products to a desired site, i.e., either into the bloodstream or into saliva, as appropriate for clinical applications.

To help understand signals involved in RSP sorting *in vivo*, we tested two hEpo fusion proteins in rat submandibular glands after gene transfer. In addition to testing a hEpo-hGH construct previously examined in mice [23], we also constructed a new fusion protein with hEpo at the C-terminus of hGH (hGH-hEpo). We hypothesized that both constructs could re-direct immunoreactive hEpo into the exocrine pathway, i.e., to saliva.

Materials and methods

Plasmids. Coding sequences of hEpo and hGH were fused with PCR using splicing by overlap extension (Advantage HF PCR kit from BD Biosciences Clontech) [24]. Oligonucleotides spanning the desired fusion site and encoding EcoRI and BamHI were designed (for the hEpo-hGH construct, hEpo, F1 5'-CGGAATTCGATG GGGGTGCACGAATG-3' and R1 5'-GGGAGCCTGCAGCCATTCTGTCC

* Corresponding author. Address: Radiation Biology Branch, Building 10, Room B3B69, MSC-1002, NCI/NIH, 10 Center Drive, Bethesda, MD 20892-1190, USA. Fax: +1 301 480 2238.

E-mail address: ysamuni@mail.nih.gov (Y. Samuni).

CCTGTCCTGCA-3'; hGH, F2 5'-ATGGCTGCAGGCTCCC-3' and R2 5'-CGCGGATCCGCGCTAGAAGCCACAGCTGCC-3'; for the hGH-hEpo construct, hGH, F1 5'-CGGAATTCGATGGCTGCAGGCTCCC-3' and R1 5'-ATTCTGACACCCCATGAAGCCACAGCTGCC-3'; hEpo, F2 5'-ATGGGGTGCACGAAT-3' and R2 5'-CGCGGATCCGCGCTCATCTG TCCCTGTCTG-3'). These primers were then used to produce two initial PCR products for each construct. The products were next hybridized with their respective flanking primers (F1 and R2) to produce the full-length chimeric cDNA of hEpo-hGH (hEpo fused to the 5' end of hGH) and hGH-hEpo (hGH fused to the 5' end of hEpo). PCR products were directionally cloned into the expression vector pAC-CMV-pLpA and the resultant plasmids, pAC-CMV-hEpo-hGH, and pAC-CMV-hGH-hEpo were sequenced and confirmed to contain the correct coding sequences.

Recombinant adenoviral vector. First-generation, E1⁻, recombinant adenoviruses (serotype 5) encoding either hEpo (AdCMV-hEpo), hEpo-hGH (AdCMVhEpo-hGH), hGH-hEpo (AdCMVhGH-hEpo), or hGH (AdCMVhGH) were constructed as previously reported [25] by cotransfection of the shuttle plasmid pAC-CMV-pLpA with the corresponding transgenes, together with the adenoviral plasmid pJM17 into 293 human embryonic kidney (HEK) cells. The vectors were amplified in HEK 293 cells and purified by two rounds of CsCl gradient centrifugation as described [26]. Purified vectors were dialyzed against 4 L of dialysis buffer containing 10% glycerol, 0.1 M Tris (pH 7.4), 5 mM MgCl₂, for 4 h at 4 °C and stored in aliquots at -80 °C for later use. Vectors were titered by quantitative PCR (ABI Prism 7700, Applied Biosystems, Foster City, CA) with primers from the E2 region of adenovirus, E2q1 (5'-GCAG AACCACAGCACAGTGT-3') and E2q2 (5'-TCCACGATTCTCTTCT AAGCTA-3').

Cell transduction and Western blot analysis. Correct expression of the hEpo-hGH and hGH-hEpo fusion proteins was evaluated in HEK 293 cells. Cells were grown in IMEM (improved minimal essential medium, Eagle's) supplemented with 10% bovine serum, 100 U/ml penicillin G, 100 µg/ml streptomycin (all from Biosource, Camarillo, CA) at 37 °C in a humidified 5% CO₂ atmosphere incubator. Cells were transduced with 100 particles/cell of AdCMVhEpo, AdCMVhEpo-hGH or AdCMVhGH-hEpo, in 6-well plates. 48 h after transduction the conditioned medium (without serum) was collected, centrifuged at 3000 rpm for 3 min and used in ELISAs for hEpo and hGH (see below). The cells were then rinsed with PBS, harvested, lysed with M-PER protein extraction reagent (Pierce), centrifuged at 1000g for 10 min to remove debris and the soluble extract was used for Western blot analysis [23].

Vector delivery to rat salivary glands. Animal experiments were approved by the National Institute of Dental and Craniofacial Research Animal Care and Use Committee and the National Institute of Health Biosafety Committee. Male Wistar rats (~250–350 g) were anesthetized with a mixture of 60 mg/ml ketamine (Phoenix Scientific, St. Joseph, MO) and 8 mg/ml xylazine (Phoenix Scientific) given intramuscularly (1 µl/g of body weight) followed by cannulation of submandibular gland ducts with modified polyethylene tubing (Intramedic PE-10, BD Diagnostic Systems, Sparks, MD). Atropine (i.m., 0.5 mg/kg body weight; Sigma, St. Louis, MO) was administered to decrease salivary flow and after 10 min, 10¹⁰ viral particles/gland (200 µl volume) of either AdCMVhEpo, AdCMVhEpo-hGH, AdCMVhGH-hEpo or AdCMVhGH were administered by retrograde ductal delivery into the submandibular glands. After 72 h, rats were anesthetized and given a subcutaneous injection of pilocarpine to induce saliva secretion (0.5 mg/ml, 1 µl/g body weight; Sigma, St. Louis, MO). Whole saliva and blood (retro-orbital vein) were collected and following separation of serum were stored at -80 °C until assayed for hEpo using a specific ELISA (see below).

In vivo distribution of secretory proteins. The concentration of each secretory protein was determined in saliva and serum samples using hEpo (Stemcell technologies, Vancouver, Canada) or

hGH (Anogen, Mississauga, Ontario, Canada) ELISAs. The distribution ratio (saliva to saliva plus serum) was calculated on the basis of the total amount of transgene product found in each fluid. For salivary calculations, we utilized an average stimulated salivary fluid secretion volume of 150 µl [27]. Thus, each measured salivary transgene protein concentration, in mU per milliliter for hEpo ELISAs (or nanogram per milliliter for hGH ELISAs), was multiplied by 0.15 to yield the total amount of the protein found in saliva. For calculating total serum levels, we multiplied the determined concentration by 4 (the approximate volume of serum in mL) [17].

Data from *in vivo* experiments were analyzed with SigmaStat software (version 2.03; Systat Systems, Point Richmond, CA), using the Mann-Whitney test, and are presented, unless otherwise stated, as means ± SEM. Differences with *p* < 0.05 were considered to be statistically significant.

Results and discussion

Media from HEK 293 cells transduced with AdCMVhEpo-hGH and AdCMVhGH-hEpo reacted positively with both the hEpo and hGH ELISAs (Fig. 1). This validated the transduction ability and function of the experimental vectors we constructed, since both ELISAs are specific for their antigens. Furthermore, proteins from the cell lysates analyzed by Western blot, immunoreacted with anti-hEpo antibody and showed the expected size of ~56 kDa for both hEpo-hGH and hGH-hEpo fusion proteins (Fig. 2). The apparent mass of hEpo and hGH are ~34 and ~22 kDa (not shown), respectively. Additionally, an immunoreactive band (~110 kDa) was also occasionally detected. The 110 kDa band likely represents the dimeric form of the fusion protein. The lack of this dimeric form in the hGH-hEpo samples would suggest that the C-terminus of hGH might be involved in this process. Indeed Glu (174) in the C-terminal α-helix has been identified as an important residue for hGH dimerization [28]. In additional experiments these products were shown to be glycosylated as they migrated at a lower molecular mass when treated with 2,N-glycosidase to remove N-linked oligosaccharides (data not shown).

We next delivered both experimental vectors to rat submandibular glands *in vivo*. Seventy-two hours following vector administration serum and saliva were collected and assayed for hEpo levels. The ratio of the total amount of immunoreactive hEpo in saliva to that found in saliva plus serum are presented for the different constructs in Fig. 3. Higher ratios indicate secretion of the construct preferentially into saliva, i.e., via an exocrine route. While the ratios of animals administered AdCMVhEpo had a mean value of 0.396 (median 0.343), those of AdCMVhEpo-hGH and AdCMVhGH-hEpo had mean values of 0.886 and 0.808, respectively (median 1 and 1). The differences in these values between the control vector (AdCMVhEpo) and the experimental groups were highly statistically significant (*p* < 0.0001 and *p* = 0.0083). The median values of the various hEpo constructs secreted into saliva and serum, as well as those for hGH, are presented in Table 1. Thus, while animals administered AdCMVhEpo secreted immunoreactive hEpo predominantly into serum as expected, animals that received either AdCMVhEpo-hGH or AdCMVhGH-hEpo secreted the immunoreactive transgene products (hEpo-hGH or hGH-hEpo) almost exclusively into saliva (Fig. 3).

Although no universal regulated pathway-sorting motifs or signals have been identified [7,8], studies of prohormone/proneuropeptide trafficking have provided evidence that sorting of these molecules to the RSP involves a receptor-mediated mechanism [29,30]. For example, in endocrine cells, sorting motifs of pro-opiomelanocortin (POMC), brain derived neurotrophic factor and proinsulin were shown to interact with membrane carboxypeptidase E, which acts as a sorting or retention receptor to target these prohormones to the RSP [31]. hGH contains a highly conserved C ter-




Fig. 1. Immunoreactive hGH and hEpo detected in media of transduced HEK 293 cells. Forty-eight hours following transduction with either AdCMVhEpo-hGH or AdCMVhGH-hEpo, media were collected and assayed with hGH (A) or hEpo (B) ELISAs. Results demonstrate positive immunoreactivity of hGH-hEpo and hEpo-hGH with both hEpo and hGH ELISAs. Data are presented as means \pm SEM ($n = 3$).




Fig. 2. Western blots from lysates of transduced cells. Lysates of cells transduced with AdCMVhEpo-hGH or AdCMVhGH-hEpo, at 100 particles/cell, were electrophoresed and reacted with anti-hEpo antibody. The predicted size of the chimeric hEpo-hGH and hGH-hEpo fusion proteins is ~ 56 kDa. The arrows to the right indicate the molecular masses of simultaneously electrophoresed protein standards. See Materials and methods, and Results, for additional details.

minimal domain that is similar to the RSP sorting domain of POMC. Indeed, it was previously shown in vitro that fusion at the C-terminus of hGH to a model constitutive pathway viral protein (a truncated vesicular stomatitis virus G sequence), re-directed the viral protein into the regulated pathway in the AtT20 model endocrine cell line [32]. Our earlier studies have suggested that the C-terminus of hEpo at least in part can influence hGH sorting and secretion from rat submandibular glands [33]. However, as shown herein, fusion of hEpo to hGH, at either the N- or C-termini, results in a significant re-direction of immunoreactive hEpo from serum into saliva (Fig. 3), i.e., both hEpo-hGH and hGH-hEpo primarily enter saliva unlike the native hEpo. Given that hGH in either configuration studied by us exerts a strong influence on hEpo secretion, it seems reasonable to suggest that additional domains within hGH, including the N-terminus, may influence hGH sorting.

In the present study performed in rats, we observed a significant difference in the secretion of hEpo-hGH compared to that we previously reported in mice [23], i.e., the re-direction of hEpo-hGH into saliva was dramatically more efficient in rats. This is surprising given the morphological and functional similarities of the submandibular glands in these two species [34], but the results herein, obtained with large numbers of animals, indicate differences in the intracellular sorting machinery of these two rodent models. Our findings, thus have given rise to a model system in which components of the sorting process may be identified by comparison of the differences in mice and rats.




Fig. 3. Ratios of immunoreactive hEpo products in saliva to that in saliva + serum. Rats were administered vector to their submandibular glands. Three days later, serum and saliva were collected and hEpo immunoreactive products measured as described in Materials and methods. Animals transduced with AdCMVhEpo-hGH, or AdCMVhGH-hEpo had statistically higher saliva/saliva plus serum ratios of immunoreactive hEpo products when compared to those found in animals transduced with AdCMVhEpo ($p < 0.0001$ and $p = 0.0083$, respectively), i.e. relatively higher levels of immunoreactive hEpo were being secreted into saliva. For these analyses, the number of rats tested was for hEpo ($n = 23$), for hEpo-hGH ($n = 24$), and for hGH-hEpo ($n = 9$). The horizontal bar represents the median value.

Table 1
Immunoreactive transgenic proteins secreted into rat saliva and serum

	Saliva	Serum
hEpo ($n = 33$)	50.61	132.4
hEpo-hGH ($n = 34$)	19.99	0
hGH-hEpo ($n = 9$)	6.55	0
hGH ($n = 5$)	10.09	0

Ten thousand viral particles were delivered to submandibular glands. Three days later, saliva and blood were collected for measurements. Total immunoreactive hEpo (in mU) or hGH (in ng) was calculated in 4 mL of serum and 0.15 mL of saliva, and median values are shown. The number (n) of animals tested with each construct is given in parentheses.

In conclusion, the present study in male rats shows that a normally constitutively secreted protein, hEpo, can be re-sorted from

an endocrine into an exocrine secretory pathway of salivary gland cells *in vivo*, and this appears influenced by hGH in an N- as well as C-terminal position. Future studies to elucidate the specific sorting motifs and intracellular molecules involved should facilitate the use of salivary glands as a gene transfer target site for clinical applications.

Acknowledgments

This research was supported by the Intramural Research Programs of the National Institute of Dental and Craniofacial Research and the National Institute of Child Health and Human Development.

References

- [1] B. Gumbiner, R.B. Kelly, Two distinct intracellular pathways transport secretory and membrane glycoproteins to the surface of pituitary tumor cells, *Cell* 28 (1982) 51–59.
- [2] R.B. Kelly, Pathways of protein secretion in eukaryotes, *Science* 230 (1985) 25–32.
- [3] P.S. Dannies, Protein hormone storage in secretory granules: mechanisms for concentration and sorting, *Endocrine Rev.* 20 (1999) 3–21.
- [4] Y.P. Loh, A. Maldonado, C. Zhan, et al., Mechanism of sorting proopiomelanocortin and proenkephalin to the regulated secretory pathway of neuroendocrine cells, *Ann. NY Acad. Sci.* 971 (2002) 416–425.
- [5] T.L. Tekirian, The central role of the trans-Golgi network as a gateway of the early secretory pathway: physiologic vs nonphysiologic protein transit, *Exp. Cell Res.* 281 (2002) 9–18.
- [6] P. Arvan, D. Castle, Protein sorting and secretion granule formation in regulated secretory cells, *Trends Cell Biol.* 2 (1992) 327–331.
- [7] P. Arvan, D. Castle, Sorting and storage during secretory granule biogenesis: looking backward and looking forward, *Biochem. J.* 332 (Pt 3) (1998) 593–610.
- [8] P. Arvan, P.A. Halban, Sorting ourselves out: seeking consensus on trafficking in the beta-cell, *Traffic* 5 (2004) 53–61.
- [9] S.U. Gorr, S.G. Venkatesh, D.S. Darling, Parotid secretory granules: crossroads of secretory pathways and protein storage, *J. Dent. Res.* 84 (2005) 500–509.
- [10] G. Griffith, K. Simons, The trans Golgi network: sorting at the exit site of the Golgi complex, *Science* 234 (1986) 438–443.
- [11] H. Lou, A.M. Smit, L.C. Coates, et al., The transmembrane domain of the prohormone convertase PC3: a key motif for targeting to the regulated secretory pathway, *Mol. Cell. Endocrinol.* 267 (2007) 17–25.
- [12] J.M. Alexander, D. Hsu, L. Penchuk, G. Heinrich, Cell-specific and developmental regulation of a nerve growth factor-human growth hormone fusion gene in transgenic mice, *Neuron* 3 (1989) 133–139.
- [13] P. Arvan, Secretory protein trafficking: genetic and biochemical analysis, *Cell Biochem. Biophys.* 40 (2004) 169–178.
- [14] J.F. Trahair, M.R. Neutra, J.I. Gordon, Use of transgenic mice to study the routing of secretory proteins in intestinal epithelial cells: analysis of human growth hormone compartmentalization as a function of cell type and differentiation, *J. Cell Biol.* 109 (1989) 3231–3242.
- [15] D. Castle, A. Castle, Intracellular transport and secretion of salivary proteins, *Crit. Rev. Oral Biol. Med.* 9 (1998) 4–22.
- [16] L. Isenman, C. Liebow, S. Rothman, The endocrine secretion of mammalian digestive enzymes by exocrine glands, *Am. J. Physiol.* 276 (1999) E223–E232.
- [17] B.J. Baum, M.E. Berkman, Y. Marmay, et al., Polarized secretion of transgene products from salivary glands *in vivo*, *Hum. Gene Ther.* 10 (1999) 2789–2797.
- [18] A.T. Hoque, L. Baccaglini, B.J. Baum, Hydroxychloroquine enhances the endocrine secretion of adenovirus-directed growth hormone from rat submandibular glands *in vivo*, *Hum. Gene Ther.* 12 (2001) 1333–1341.
- [19] X. Yan, A. Voutetakis, C. Zheng, et al., Sorting of transgenic secretory proteins in miniature pig parotid glands following adenoviral-mediated gene transfer, *J. Gene Med.* 9 (2007) 779–787.
- [20] B.J. Baum, A. Voutetakis, J. Wang, Salivary glands: novel target sites for gene therapeutics, *Trends Mol. Med.* 10 (2004) 585–590.
- [21] A. Voutetakis, I. Bossis, M.R. Kok, et al., Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders, *J. Endocrinol.* 185 (2005) 363–372.
- [22] A. Voutetakis, M.R. Kok, C. Zheng, et al., Reengineered salivary glands are stable endogenous bioreactors for systemic gene therapeutics, *Proc. Natl. Acad. Sci. USA* 101 (2004) 3053–3058.
- [23] Y. Samuni, N.X. Cawley, C. Zheng, et al., Sorting behavior of a transgenic erythropoietin-growth hormone fusion protein in murine salivary glands, *Hum. Gene Ther.* 19 (2008) 279–286.
- [24] A.N. Vallejo, R.J. Pogulis, L.R. Pease, Mutagenesis and synthesis of novel recombinant genes using PCR, in: C.W. Dieffenbach, G.S. Dveksler (Eds.), *Cold Spring Harbor Laboratory Press, Plainview, New York*, 1995, pp. 603–612.
- [25] X. He, C.M. Goldsmith, Y. Marmay, et al., Systemic action of human growth hormone following adenovirus-mediated gene transfer to rat submandibular glands, *Gene Ther.* 5 (1998) 537–541.
- [26] C. Delporte, B.C. O'Connell, X. He, et al., Adenovirus-mediated expression of aquaporin-5 in epithelial cells, *J. Biol. Chem.* 271 (1996) 22070–22075.
- [27] Y. Marmay, P.C. Fox, B.J. Baum, Fluid secretion rates from mouse and rat parotid glands are markedly different following pilocarpine stimulation, *Comp. Biochem. Physiol. A* 88 (1987) 307–310.
- [28] B.C. Cunningham, M.G. Mulkerrin, J.A. Wells, Dimerization of human growth hormone by zinc, *Science* 253 (1991) 545–548.
- [29] D.R. Cool, E. Normant, F. Shen, et al., Carboxypeptidase E is a regulated secretory pathway sorting receptor: genetic obliteration leads to endocrine disorders in Cpe (fat) mice, *Cell* 88 (1997) 73–83.
- [30] Y.P. Loh, T. Kim, Y.M. Rodriguez, N.X. Cawley, Secretory granule biogenesis and neuropeptide sorting to the regulated secretory pathway in neuroendocrine cells, *J. Mol. Neurosci.* 22 (2004) 63–71.
- [31] H. Lou, S.K. Kim, E. Zaitsev, et al., Sorting and activity-dependent secretion of BDNF require interaction of a specific motif with the sorting receptor carboxypeptidase e, *Neuron* 45 (2005) 245–255.
- [32] H.H. Moore, R.B. Kelly, Re-routing of a secretory protein by fusion with human growth hormone sequences, *Nature* 321 (1986) 443–446.
- [33] J. Wang, N.X. Cawley, A. Voutetakis, et al., Partial redirection of transgenic human growth hormone secretion from rat salivary glands, *Hum. Gene Ther.* 16 (2005) 571–583.
- [34] C.A. Pinkstaff, The cytology of salivary glands, *Int. Rev. Cytol.* 63 (1979) 141–261.